Stein Sundstrøm

Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007

Sarah Walters, Camille Maringe, Michel P. Coleman et al. · Thorax · 2013 · 541 citations · Full text

Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-Up

Stein Sundstrøm, Roy M. Bremnes, Stein Kaasa et al. · Journal of Clinical Oncology · 2002 · 501 citations

Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer

Bjørn Henning Grønberg, Roy M. Bremnes, Øystein Fløtten et al. · Journal of Clinical Oncology · 2009 · 289 citations · Full text

Cancer Quality, Gemcitabine Plus Carboplatin, Cancer Management +17

Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program

Armando Santoro, Mary O’Brien, Rolf A. Stahel et al. · Journal of Thoracic Oncology · 2008 · 247 citations

Chemonaïve Patients, Malignant Pleural Mesothelioma, Medicine +6

The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up

Roy M. Bremnes, Stein Sundstrøm, Ulf Aasebø et al. · Lung Cancer · 2003 · 191 citations

Prognostic Factors, Prognostic Biomarkers, Minimum 5 +8